Trials / Recruiting
RecruitingNCT05582876
Multicenter Assessment of Clinical Utility PET / MR With the Use of the Radiotracer 68Ga-PSMA-11 in Therapy Planning Personalized in Patients With Prostate Cancer
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 366 (estimated)
- Sponsor
- Medical University of Bialystok · Academic / Other
- Sex
- Male
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The aim of multicentre phase 3 trial is evidence diagnostic value of 68Ga-PSMA-11 (in PET / CT and PET / MR techniques) in patients with high-risk and intermediate prostate cancer before radical treatment and in diagnosed patients biochemical recurrence after radical treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Radiopharmaceutical 68Ga-PSMA-11 PET/CT | The radiopharmaceutical will be administered intravenously in doses with an activity of 1.8-2.2 MBq / kg b.w. |
Timeline
- Start date
- 2023-01-10
- Primary completion
- 2026-01-31
- Completion
- 2026-03-31
- First posted
- 2022-10-17
- Last updated
- 2025-05-08
Locations
7 sites across 1 country: Poland
Source: ClinicalTrials.gov record NCT05582876. Inclusion in this directory is not an endorsement.